ctDNA-guided dose holidays for lung cancer targeted therapy
Use tumour DNA in the blood as the signal to pause and restart a lung cancer pill, keeping the tumour in check while slowing the rise of resistant cells.
Adaptive therapy needs a fast, quantitative burden marker. In EGFR- and ALK-driven lung cancer, ctDNA falls to undetectable within weeks of TKI and rises before scans show progression. The proposal is a rules-based algorithm: pause the TKI when ctDNA has been undetectable for two consecutive draws, restart at reappearance, and compare with continuous dosing.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Wrong doses · Most drug doses were chosen as the highest a person can tolerate, which is often more than they need.
Pages like this
not linked directly; found by shared links- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Osimertinib, Circulating tumour DNA (ctDNA), Wrong doses, Acquired resistance to every therapy.
- IdeaA clone report from blood at every treatment cycle
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Acquired resistance to every therapy.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaTest intermittent dosing of targeted drugs to delay resistance, with honest priors
Shares Circulating tumour DNA (ctDNA), Wrong doses, Acquired resistance to every therapy, Small-molecule kinase inhibitors.
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Non-small-cell lung cancer.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Osimertinib, Acquired resistance to every therapy, EGFR, Liquid biopsy (ctDNA).
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- IdeaLook for the resistant sub-population before the first dose
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, EGFR, Liquid biopsy (ctDNA).